fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Empagliflozin

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Jardiance · DIN 02443937 · 10 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Jardiance · DIN 02443937 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2016-05-31 Health Canada: Marketed since 2015-08-11 · brand JARDIANCE · ATC A10BK03 EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 10 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jardiance: Formulary list price $2.89 per unit (the source does not state the unit; exact figure $2.8868). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443937)

Source record
DIN 02443937: Jardiance Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002057; group id 743; item number 1815; lccId None; manufacturer id BOE Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $2.8868; ministry $2.8868 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443937 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92871 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.
Shortage status: resolved shortage (ended September 11, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443937
Shortage record checked October 6, 2026

Jardiance · DIN 02443945 · 25 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Jardiance · DIN 02443945 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2016-05-31 Health Canada: Marketed since 2015-08-11 · brand JARDIANCE · ATC A10BK03 EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 25 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jardiance: Formulary list price $2.89 per unit (the source does not state the unit; exact figure $2.8868). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443945)

Source record
DIN 02443945: Jardiance Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002058; group id 743; item number 1816; lccId None; manufacturer id BOE Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $2.8868; ministry $2.8868 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443945 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92872 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.
Shortage status: resolved shortage (ended July 29, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443945
Shortage record checked October 6, 2026

Other products in the same Health Canada class (A10B, A10BK): coverage varies; not interchangeable

  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit
  • Dapagliflozin + metformin (Xigduo): general benefit
  • Gliclazide (Diamicron MR): general benefit, not a benefit
  • Glyburide (Apo-Glyburide): general benefit, not a benefit
  • Linagliptin (Trajenta): general benefit

11 more in the class list below

Empagliflozin & metformin

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Synjardy · DIN 02456575 · 5 mg & 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Synjardy · DIN 02456575 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN, A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 5 MG, METFORMIN HYDROCHLORIDE 500 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Synjardy: Formulary list price $1.45 per unit (the source does not state the unit; exact figure $1.4535). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456575)

Source record
DIN 02456575: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002066; group id 744; item number 1818; lccId None; manufacturer id BOE Source form: Tab; strength: 5mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456575 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94357 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.
Shortage status: resolved shortage (ended June 20, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456575
Shortage record checked October 6, 2026

Synjardy · DIN 02456583 · 5 mg & 850 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Synjardy · DIN 02456583 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN, A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 5 MG, METFORMIN HYDROCHLORIDE 850 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Synjardy: Formulary list price $1.45 per unit (the source does not state the unit; exact figure $1.4535). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456583)

Source record
DIN 02456583: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002067; group id 744; item number 1819; lccId None; manufacturer id BOE Source form: Tab; strength: 5mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456583 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94358 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456583
Shortage record checked October 6, 2026

Synjardy · DIN 02456591 · 5 mg & 1000 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Synjardy · DIN 02456591 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN, A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 1000 MG, EMPAGLIFLOZIN 5 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Synjardy: Formulary list price $1.45 per unit (the source does not state the unit; exact figure $1.4535). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456591)

Source record
DIN 02456591: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002068; group id 744; item number 1817; lccId None; manufacturer id BOE Source form: Tab; strength: 5mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456591 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94359 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456591
Shortage record checked October 6, 2026

Synjardy · DIN 02456605 · 12.5 mg & 500 mg · tablet

General benefitMarketed · checked November 16, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Synjardy · DIN 02456605 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 12.5 MG, METFORMIN HYDROCHLORIDE 500 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Synjardy: Formulary list price $1.45 per unit (the source does not state the unit; exact figure $1.4535). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456605)

Source record
DIN 02456605: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002069; group id 744; item number 1821; lccId None; manufacturer id BOE Source form: Tab; strength: 12.5mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456605 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94360 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.
Shortage status: resolved shortage (ended April 11, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456605
Shortage record checked October 6, 2026

Synjardy · DIN 02456613 · 12.5 mg & 850 mg · tablet

General benefitMarketed · checked November 16, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Synjardy · DIN 02456613 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 12.5 MG, METFORMIN HYDROCHLORIDE 850 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Synjardy: Formulary list price $1.45 per unit (the source does not state the unit; exact figure $1.4535). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456613)

Source record
DIN 02456613: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002070; group id 744; item number 1822; lccId None; manufacturer id BOE Source form: Tab; strength: 12.5mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456613 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94361 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456613
Shortage record checked October 6, 2026

Synjardy · DIN 02456621 · 12.5 mg & 1000 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Synjardy · DIN 02456621 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN, A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 12.5 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Synjardy: Formulary list price $1.45 per unit (the source does not state the unit; exact figure $1.4535). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456621)

Source record
DIN 02456621: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002071; group id 744; item number 1820; lccId None; manufacturer id BOE Source form: Tab; strength: 12.5mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456621 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94362 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456621
Shortage record checked October 6, 2026

Other products in the same Health Canada class (A10B, A10BK): coverage varies; not interchangeable

  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit
  • Dapagliflozin + metformin (Xigduo): general benefit
  • Gliclazide (Diamicron MR): general benefit, not a benefit
  • Glyburide (Apo-Glyburide): general benefit, not a benefit
  • Linagliptin (Trajenta): general benefit

11 more in the class list below

Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL 68:20:02 Oral Anti-Diabetic Agents

CANAGLIFLOZIN

· 8 products · General benefit · strengths: 100mg, 300mg · Tab

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

GLICLAZIDE

· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab

GLYBURIDE

· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab

LINAGLIPTIN

· 1 products · General benefit · strengths: 5mg · Tab

LINAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

METFORMIN HCL

· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

SITAGLIPTIN

· 48 products · General benefit · strengths: 25mg, 50mg, 100mg · Tab

SITAGLIPTIN & METFORMIN

· 41 products · General benefit · strengths: 50mg & 1000mg, 50mg & 500mg, 100mg & 1000mg, 50mg & 850mg · ER Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:02 and 5 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: heart failure
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DAPAGLIFLOZIN DAPAGLIFLOZIN · General benefit Heart Failure FORXIGA is indicated in adults, as an adjunct to standard of care therapy, for the treatment of heart failure to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure and urgent heart failure visit. PM: https://pdf.hres.ca/dpd_pm/00078350.PDF; date Dec 10, 2014; DIN 02435462; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS Type 2 diabetes mellitus (T2DM) Monotherapy: JARDIANCE (empagliflozin) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with T2DM for whom metformin is inappropriate due to contraindications or intolerance. Add-on combination: JARDIANCE is indicated in adult patients with T2DM to improve glycemic control in combination with: • metformin • metformin and a sulfonylurea • pioglitazone (alone or with metformin) • linagliptin and metformin • basal or prandial insulin (alone or with metformin) when metformin alone or the existing therapy listed above, along with diet and exercise, do not provide adequate glycemic control. Add-on combination in patients with established cardiovascular disease: JARDIANCE is indicated as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in patients with T2DM and established cardiovascular disease. Important Limitations of Use: Use of JARDIANCE with insulin mix (regular or analogue mix) has not been studied. Therefore, JARDIANCE should not be used with insulin mix. Heart Failure (HF) JARDIANCE … https://pdf.hres.ca/dpd_pm/00081256.PDF PM date: JUL 23, 2015 Source product: JARDIANCE; DIN 02443937; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS SYNJARDY (empagliflozin and metformin hydrochloride tablets) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on: o metformin; o sulfonylurea in combination with metformin; o pioglitazone in combination with metformin; o insulin in combination with metformin; • In patients already being treated and achieving glycemic control with: o metformin and empagliflozin as separate tablets; o sulfonylurea in combination with metformin and empagliflozin as separate tablets; o pioglitazone in combination with metformin and empagliflozin as separate tablets; o insulin in combination with metformin and empagliflozin as separate tablets. Important Limitations of Use: In combination therapy, use of empagliflozin with insulin mix (regular or analogue mix) has not been studied. Therefore, SYNJARDY should not be used with insulin mix (see 14 CLINICAL TRIALS). 1.1 Pediatrics Pediatrics (<18 years of age): SYNJARDY should not be used in pediatric pati… https://pdf.hres.ca/dpd_pm/00081258.PDF PM date: JUL 29, 2016 Source product: SYNJARDY; DIN 02456575; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18